Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + ME...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Discov
Main Authors: Erkes, Dan A., Cai, Weijia, Sanchez, Ileine M., Purwin, Timothy J., Rogers, Corey, Field, Conroy O., Berger, Adam C., Hartsough, Edward J., Rodeck, Ulrich, Alnemri, Emad S., Aplin, Andrew E.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007378/
https://ncbi.nlm.nih.gov/pubmed/31796433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0672
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker